Methyl Alcohol

Methyl Alcohol

SCHEMBL3873053

CO.CO.CO.CO.CO.CO.CO.CO.OCC(Cl)Cl

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.43
TDP1 Q9NUW8 2/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 3/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL15486105 1.00
Methyl Alcohol SCHEMBL14631040 1.00 TSHR (0.43) TSHRTDP1TP53ALDH1A1LMNA
Methyl Alcohol SCHEMBL1303760 1.00 TSHR (0.43) TSHRTDP1TP53ALDH1A1LMNA
Methyl Alcohol SCHEMBL2938777 1.00
SCHEMBL949 0.91
Methylene Chloride SCHEMBL8405127 0.89 TSHR (0.42) TSHRTDP1TP53ALDH1A1
Methylamine SCHEMBL7494882 0.87
Alcohol SCHEMBL7158313 0.87
Water SCHEMBL4995754 0.86
SCHEMBL8157042 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099456-A2 N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS Progenics Pharmaceuticals, Inc. (US) 2009-09-16 EP disclosed
WO-2009067275-A1 N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS PROGENICS PHARMACEUTICALS, INC (US) 2009-05-28 WO disclosed
US-20080234306-A1 N-Oxides of 4,5-Epoxy-Morphinanium Analogs PROGENICS PHARMACEUTICALS, INC. (US) 2008-09-25 US disclosed
WO-2008070462-A2 N-OXIDES OF 4,5-EPOXY-MORPHINANIUM ANALOGS PROGENICS PHARMACEUTICALS, INC. (US) 2008-06-12 WO disclosed
EP-0979244-B1 NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AVENTIS PHARMA SA (FR) 2005-03-02 EP disclosed
US-6683095-B2 ANTICARCINOGENIC AGENTS; ANTIPROLIFERATION AGENTS LG LIFE SCIENCES LTD. (KR) 2004-01-27 US disclosed
US-20030125356-A1 Cdk inhibitors having 3-hydroxychromen-4-one structure LG LIFE SCIENCES LTD. (KR) 2003-07-03 US disclosed
EP-1280789-A1 CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE LG Life Sciences Ltd. (KR) 2003-02-05 EP disclosed
WO-2001083469-A1 CDK INHIBITORS HAVING 3-HYDROXYCHROMEN-4-ONE STRUCTURE LG LIFE SCIENCES LTD. (KR) 2001-11-08 WO disclosed
EP-0979244-A1 NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Aventis Pharma S.A. (FR) 2000-02-16 EP disclosed
WO-1998049193-A1 NOVEL CYCLOSPORIN DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME RHONE-POULENC RORER S.A. (FR) 1998-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125356-A1 Cdk inhibitors having 3-hydroxychromen-4-one structure CDK4, CDK3, CDK6 TSHR 4555/4885TDP1 2335/4885TP53 453/4885
US-20080234306-A1 N-Oxides of 4,5-Epoxy-Morphinanium Analogs OPRM1, OPRD1, OPRK1 TSHR 1793/4885TDP1 3929/4885TP53 4728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.